Publications database

Displaying 51 - 60 of 142

Risk assessments

Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of...

Implementation reports

EMCDDA–Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA

This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control...

Cover of the risk assessment

Risk assessments

Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018...

Cover of the risk assessment

Risk assessments

Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1 H -indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In...

Cover of the AB-CHMINACA risk assessment

Risk assessments

Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on N -(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H -indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In...

Cover of the risk assessment

Risk assessments

Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on N -(4-fluorophenyl)-2-methyl- N -[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In...

Cover of the risk assessment

Risk assessments

Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4- yl]oxolane-2-carboxamide (THF-F) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on N -phenyl- N -[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide (THF-F), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In...

European Drug Report

European Drug Report 2018: Trends and Developments

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with...

Rapid communication

Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation — an update from the EU Early Warning System

In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early...

Rapid communication

New psychoactive substances in prison

This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence...